Merck's earnings call highlighted strong first-quarter results, exceeding expectations and boosting full-year EPS guidance.  Management's tone is upbeat, emphasizing product successes, especially for GARDASIL, SINGULAIR, and newer launches like JANUVIA, but also acknowledging the challenges of patent expirations and maintaining growth momentum.  The stock is likely to see a positive impact in the short term, driven by the strong earnings and the raised guidance.
[1]
